Application of KAT2B binding histone demethylase compound and medicament for inhibiting proliferation of bile duct cancer

The KAT2B binding to histone demethylase complex regulates p21 expression and binds to the HDAC inhibitor Vorinostat, and prepares liposome nanoparticle agents, which solves the problem of insufficient molecular targets of cholangiocarcinoma and realizes the proliferation and metastasis of cholangiocarcinoma cells effective inhibition.

CN118924908APending Publication Date: 2024-11-12LISHUI CENT HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411012986.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art has insufficient research on the molecular mechanism of cholangiocarcinoma and no effective molecular targets have been found to inhibit the proliferation and metastasis of cholangiocarcinoma.

Method used

Provide a KAT2B binding histone demethylase complex, including KAT2B, KDM1A, KDM3B and KDM6B, promotes the expression of tumor suppressor genes by regulating the expression of downstream target gene p21, and combines with the HDAC inhibitor Vorinostat, to prepare for use in Liposome nanoparticle agent that inhibits the proliferation of cholangiocarcinoma.

Benefits of technology

Effectively inhibit the proliferation and metastasis of cholangiocarcinoma cells, improve the sensitivity of cholangiocarcinoma cells to HDAC inhibitors, and provide potential molecular targets and treatment options for cholangiocarcinoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924908A_ABST
    Figure CN118924908A_ABST
Patent Text Reader

Abstract

The invention relates to application of a KAT2B combined histone demethylase compound and a medicament for inhibiting proliferation of bile duct cancer, belongs to the technical field of bile duct cancer, and solves the problem that no effective molecular target spot for bile duct cancer is found in the prior art. The KAT2B binding histone demethylase compound is prepared from KAT2B, KDM1A, KDM3B and KDM6B, and the KAT2B binding histone demethylase compound is prepared from KAT2B, KDM1A, KDM3B and KDM6B. KAT2B is specifically combined with KDM1A, KDM3B and KDM6B to regulate and control expression of a downstream gene p21, so that proliferation and metastasis of bile duct cancer are inhibited; in the medicament, the KAT2B overexpression plasmid promotes the overexpression of the KAT2B, the overexpressed KAT2B improves the sensitivity of the bile duct cancer cells to the HDAC inhibitor so as to inhibit the growth of the bile duct cancer cells, and in addition, the overexpressed KAT2B is combined with KDM1A, KDM3B and KDM6B so as to inhibit the proliferation and metastasis of the bile duct cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of cholangiocarcinoma, and in particular to an application of a KAT2B-binding histone demethylase complex and a medicament for inhibiting the proliferation of cholangiocarcinoma. Background Art

[0002] Cholangiocarcinoma (CCA) is an aggressive malignant tumor arising from different locations within the biliary system. It is highly lethal and can be divided into intrahepatic adenocarcinoma (iCCA), perihilar adenocarcinoma (pCCA), and distal adenocarcinoma (dCCA). Cholangiocarcinoma is the second most common primary liver malignancy after liver cancer, accounting for about 15% of all primary liver cancers. Although cholangiocarcinoma is rare, its incidence and mortality have continued to rise worldwide in the past few decades (the incidence of cholangiocarcinoma is 0.3-6 / 100,000 people per year, and the mortality rate is 1-6 / 100,000 people), especially in South Korea, China, and Thailand, where the annual incidence of cholangiocarcinoma is as high as 6 / 100,000 people. Unfortunately, it is difficult to detect in the early stages, and when it is discovered, it is already in the middle and late stages. Existing technologies have not studied the molecular mechanisms of cholangiocarcinoma enough, and no effective molecular targets for cholangiocarcinoma have been found. Summary of the invention

[0003] In view of the above analysis, the embodiments of the present invention aim to provide an application of a KAT2B-binding histone demethylase complex and a drug for inhibiting the proliferation of cholangiocarcinoma, so as to solve the problem that no effective molecular targets for cholangiocarcinoma have been found.

[0004] In one aspect, an embodiment of the present invention provides a KAT2B-binding histone demethylase complex, wherein the KAT2B-binding histone demethylase complex comprises KAT2B, KDM1A, KDM3B and KDM6B.

[0005] In a second aspect, the present invention also provides the use of the above-mentioned KAT2B-binding histone demethylase complex in inhibiting the proliferation of cholangiocarcinoma.

[0006] Preferably, the KAT2B binds to the histone demethylase complex to promote the expression of the tumor suppressor gene p21.

[0007] Preferably, the KAT2B binds to the histone demethylase complex and promotes the expression of gene p21 by participating in the transcriptional activation of the tumor suppressor gene p21.

[0008] Preferably, the sensitivity of cholangiocarcinoma cells to HDAC inhibitors is increased by KAT2B.

[0009] In a third aspect, the present invention further provides a drug for inhibiting the proliferation of bile duct cancer, wherein the drug is a liposome nanoparticle, and the drug comprises a KAT2B overexpression plasmid and an HDAC inhibitor.

[0010] Preferably, the mass ratio of the KAT2B overexpression plasmid to the HDAC inhibitor is 18-25:1.

[0011] Preferably, the HDAC inhibitor is Vorinostat.

[0012] In a fourth aspect, the present invention provides a method for preparing the above-mentioned medicament, the preparation method comprising:

[0013] Step (1): dissolving egg yolk phosphatidylcholine E80, cholesterol Chol, KAT2B overexpression plasmid and HDAC inhibitor in a solvent to obtain a drug solution;

[0014] Step (2): removing the solvent by rotary evaporation to obtain a lipid film;

[0015] Step (3): hydrating the lipid film to form a liposome solution;

[0016] Step (4): Ultrasonicate the liposome solution to obtain a uniform liposome drug-loaded solution.

[0017] Preferably, in step (1), the solvent is a mixture of chloroform and methanol.

[0018] Compared with the prior art, the present invention can achieve at least one of the following beneficial effects:

[0019] 1. The KAT2B-binding histone demethylase complex of the present invention can regulate the expression of downstream target genes. Specifically, KAT2B specifically binds to KDM1A, KDM3B, and KDM6B to regulate the expression of the downstream gene p21, thereby inhibiting the proliferation and metastasis of cholangiocarcinoma. This provides new insights into how KAT2B regulates transcription by coordinating different chaperone protein complexes, provides a molecular basis for understanding the pathophysiological functions of KAT2B, and provides potential molecular targets for cholangiocarcinoma.

[0020] 2. In the KAT2B-binding histone demethylase complex of the present invention, KAT2B can increase the sensitivity of cholangiocarcinoma cells to HDAC inhibitors, thereby inhibiting the growth of cholangiocarcinoma cells.

[0021] 3. In the agent for inhibiting the proliferation of cholangiocarcinoma of the present invention, the KAT2B overexpression plasmid promotes KAT2B overexpression. On the one hand, the overexpressed KAT2B increases the sensitivity of cholangiocarcinoma cells to HDAC inhibitors, thereby inhibiting the growth of cholangiocarcinoma cells. On the other hand, the overexpressed KAT2B binds to KDM1A, KDM3B, and KDM6B to inhibit the proliferation and metastasis of cholangiocarcinoma.

[0022] In the present invention, the above-mentioned technical solutions can also be combined with each other to achieve more preferred combination solutions. Other features and advantages of the present invention will be described in the subsequent description, and some advantages can become obvious from the description, or can be understood by practicing the present invention. The purpose and other advantages of the present invention can be realized and obtained through the contents particularly pointed out in the description and the drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] The drawings are only for the purpose of illustrating particular embodiments and are not to be considered limiting of the present invention. Like reference symbols denote like components throughout the drawings.

[0024] Figure 1 The effect of KAT2B gene expression on the survival curve of patients with cholangiocarcinoma;

[0025] Figure 2 This is the qRT-PCR detection result of KAT2B gene;

[0026] Figure 3 This is the result of Western blotting of KAT2B gene;

[0027] Figure 4 To detect the expression of KAT2B in the cancer and adjacent tissues of patients with cholangiocarcinoma by immunotissue microarray;

[0028] Figure 5 To detect the expression of KAT2B in the cancer and adjacent tissues of patients with cholangiocarcinoma by immunotissue microarray;

[0029] Figure 6 The results of separation and silver staining using SDS-PAGE gel were as in Example 1;

[0030] Figure 7 The results of immunoprecipitation detection using anti-KAT2B antibody for IP and anti-HAT1, KDM1A, KDM3B and KDM6B antibodies for IB are shown in Example 1;

[0031] Figure 8 The immunoprecipitation results of Example 1 are as follows: IP with anti-HAT1, KDM1A, KDM3B and KDM6B antibodies and IB with anti-KAT2B antibodies;

[0032] Fig. 9 The results of Example 1 using immunofluorescence co-localization to detect whether KAT2B co-localizes with histone demethylases KDM1A, KDM3B and KDM6B in cells;

[0033] Fig.10The results of high-throughput RNA deep sequencing (RNA-seq) on KAT2B knockdown HUCCT1 cells and control cells in Example 1;

[0034] Fig.11 This is the result of gene set enrichment analysis in Example 1 when KAT2B is knocked down;

[0035] Fig.12 The results of KEGG pathway enrichment analysis in Example 1;

[0036] Fig.13 The results of the biological process (BP) analysis of Example 1 are as follows;

[0037] Fig.14 The molecular function (MF) analysis results of Example 1;

[0038] Fig.15 The results of cell component (CC) analysis;

[0039] Fig.16a The results of quantitative real-time PCR (qPCR) for verifying the expression of KAT2B, KDM1A, KDM3B and KDM6B in RBE cells in Example 1;

[0040] Fig.16b The results of quantitative real-time PCR (qPCR) for verifying the expression of KAT2B, KDM1A, KDM3B and KDM6B in HUCCT1 cells in Example 1;

[0041] Fig.17a The results of the knockdown efficiency of KAT2B, KDM1A, KDM3B and KDM6B in RBE cells in Example 1 are shown;

[0042] Fig.17b The results of the knockdown efficiency of KAT2B, KDM1A, KDM3B and KDM6B in HUCCT1 cells in Example 1 are shown;

[0043] Fig.18 For Example 1, a ChIP experiment was performed in HUCCT1 cells using anti-KAT2B, KDM1A, KDM3B and KDM6B or control IgG antibodies, and the ChIP results were quantitatively analyzed using qPCR;

[0044] Fig.19 HUCCT1 cells were infected with control shRNA, shKAT2B, shKDM1A, shKDM3B, and shKDM6B as in Example 1, and the recruitment of the indicated proteins on the CDKN1A promoter was analyzed by ChIP qPCR, with IgG as a negative control;

[0045] Fig. 20 For Example 1, chromatin-bound proteins were extracted from HUCCT1 cells transfected with control shRNA, shKAT2B, shKDM1A, shKDM3B and shKDM6B, and their expression levels were analyzed, with histone H3 as an internal reference;

[0046] Fig.21 The results of EdU incorporation assay using the fluorescence method in Example 2; KAT2B knockdown can inhibit the proliferation of HUCCT1 cells, and p21 is overexpressed on the basis of KAT2B knockout, and the proliferation-promoting phenomenon of KAT2B knockout tumor cells is prevented;

[0047] Fig. 22 The quantitative statistical results of the EdU experiment in Example 2;

[0048] Fig.23 This is the Trans-well invasion experiment in Example 2;

[0049] Fig.24 The quantitative statistical results of the invasion experiment in Example 2;

[0050] Fig.25 The knockout and overexpression lentiviral transfection quality check of cells used in Example 2 was verified by Western Blots;

[0051] Fig.26 The growth of tumors after subcutaneous injection of HUCCT1 cells stably expressing shKAT2B or overexpressing KAT2B into BALB / c nude mice in Example 2;

[0052] Fig. 27 The tumor weight / volume statistics of mice in the KAT2B interference or KAT2B overexpression group and the control group in Example 2;

[0053] Fig.28 This is a diagram showing quantitative observation of lung metastasis using bioluminescence imaging in Example 2;

[0054] Fig.29 This is a picture of the mouse lung after anatomical sectioning and staining in Example 2;

[0055] Fig.30 This is the statistical diagram of counting metastatic foci in Example 2;

[0056] Fig.31 To analyze the activity of HUCCT1 cells expressing KAT2B under different concentrations of HDAC inhibitor (Vorinostat) using CCK8 method;

[0057] Fig.32To analyze the proliferation capacity of HUCCT1 cells overexpressing KAT2B after Vorinostat treatment using colony formation assay;

[0058] Fig.33 This is the particle size distribution diagram of the KV liposome nanoparticles obtained in Example 5;

[0059] Fig.34 The surface potential detection results of the KV liposome nanoparticles and the control nanoparticles (without Vorinostat and KAT2B overexpression plasmid) obtained in Example 5;

[0060] Fig.35 This is an electron microscopic image of the KV nanoparticles obtained in Example 5;

[0061] Fig.36 This is a statistical diagram of the encapsulation efficiency of KAT2B overexpression plasmid and Vorinostat in KV nanoparticles obtained in Example 5;

[0062] Fig.37 The figure is a statistical diagram of the drug loading rate of KAT2B overexpression plasmid and Vorinostat in KV nanoparticles obtained in Example 5;

[0063] Fig.38 This is a staining effect diagram of the KV nanoparticles obtained in Example 5 on the growth of cholangiocarcinoma cells;

[0064] Fig.39 This is a statistical graph of the effect of KV nanoparticles obtained in Example 5 on the growth of cholangiocarcinoma cells. DETAILED DESCRIPTION

[0065] The preferred embodiments of the present invention are described in detail below in conjunction with the accompanying drawings, wherein the accompanying drawings constitute a part of this application and are used together with the embodiments of the present invention to illustrate the principles of the present invention, but are not used to limit the scope of the present invention.

[0066] The inventors conducted bioinformatics analysis on cholangiocarcinoma and adjacent tissues in the TCGA database and found a significantly differentially expressed gene, KAT2B. Cholangiocarcinoma patients with high KAT2B expression had a better disease-free survival rate (HR < 1) than those with low KAT2B expression, which could reduce disease progression by 40%, and the P value was significant. Table 1 shows the cox regression analysis results of KAT2B in TCGA clinical data, as well as the HR and P value.

[0067] Table 1

[0068] ID HR HR.95L HR.95H P-value KAT2B 0.60 0.37 0.96 0.03

[0069] Then, Log-rank test was used to test whether there was a difference in the effect of gene expression on the survival curve of patients with cholangiocarcinoma, and the P value was used as the basis for whether the experiment was positive. Figure 1 As shown, the survival curve analysis showed that the expression of KAT2B was correlated with the disease-free survival (DFS) of patients with cholangiocarcinoma. Combined with Table 1, it can be seen that KAT2B was positively correlated with the DFS of patients with cholangiocarcinoma (P < 0.05).

[0070] The above analysis results were verified by qRT-PCR, immunohistochemistry (IHC) and protein immunoblotting. Five pairs of cholangiocarcinoma and adjacent tissue specimens were collected from the clinic, and total protein and mRNA were extracted to detect the expression of genes in the tissues. At the mRNA level, the KAT2B gene was detected, and the qRT-PCR results showed (e.g. Figure 2 As shown in the figure, KAT2B has significant difference, and the mRNA level of KAT2B in cholangiocarcinoma tissue is significantly lower than that in adjacent tissues; the results of western blot detection are as follows Figure 3 As shown in the figure, the expression of KAT2B in cholangiocarcinoma tissues was significantly lower than that in adjacent tissues, which indicates that KAT2B is related to the occurrence and development of cholangiocarcinoma. The expression of KAT2B in cholangiocarcinoma and adjacent tissues of patients with cholangiocarcinoma was detected by immunotissue microarray. The results are shown in the figure. Figure 4 and Figure 5 As shown, KAT2B is hardly expressed in tumor tissues, but is relatively highly expressed in adjacent paracancerous tissues.

[0071] Then, it was verified in clinical tumor specimens that KAT2B was lowly expressed in cholangiocarcinoma compared with adjacent adjacent tissues. To further understand the functional role of KAT2B in cholangiocarcinoma, phenotypic experiments such as EdU, growth curve, clone formation, and Trans-well were performed to prove that KAT2B played a role in inhibiting tumor growth and invasion in cholangiocarcinoma. In the study, it was found that KAT2B was significantly lowly expressed in cholangiocarcinoma tissues, and its expression level was significantly positively correlated with disease-free survival.

[0072] However, it is still unclear whether KAT2B works together with other genes to regulate the proliferation and metastasis of cholangiocarcinoma.

[0073] Based on this, the present invention provides a KAT2B-binding histone demethylase complex, wherein the KAT2B-binding histone demethylase complex comprises lysine acetyltransferase KAT2B, histone demethylase KDM1A, histone demethylase KDM3B and histone demethylase KDM6B.

[0074] Compared with the prior art, the KAT2B of the present invention binds to the histone demethylase complex and inhibits the proliferation and metastasis of cholangiocarcinoma by regulating the expression of the downstream target gene p21, which is different from the prior art that KAT2B inhibits the YAP signaling pathway by binding to the transcription factor sp1 to promote the expression of the downstream NF2 gene, thereby inhibiting the growth of cholangiocarcinoma cells. The present invention provides new insights into how KAT2B regulates transcription by coordinating different chaperone protein complexes, provides a molecular basis for understanding the pathophysiological functions of KAT2B, and provides potential molecular targets for cholangiocarcinoma.

[0075] Specifically, KAT2B acts together or cross-acts with KDM1A, KDM3B and KDM6B on the same target gene site, thereby regulating the transcription of downstream genes. Experiments have confirmed that KAT2B can interact with histone demethylases DM1A, KDM3B and KDM6B in vivo. KAT2B interacts with histone demethylases DM1A, KDM3B and KDM6B, and all are closely related to the transcriptional regulation of genes.

[0076] Among them, it is shown that KAT2B is related to cell metabolism regulation and proliferation, and KAT2B participates in epigenetic regulation and protein synthesis. KAT2B inhibits the proliferation of cholangiocarcinoma cells by affecting the transcription of genes related to the cell cycle pathway. KAT2B specifically binds to KDM1A, KDM3B, and KDM6B, and promotes the acetylation of H3K14 and H4K8 on the p21 promoter through epigenetics. KAT2B is associated with KDM1A, KDM3B, and KDM6B, promoting the expression of the tumor suppressor gene p21. KAT2B binds to KDM1A, KDM3B, and KDM6B to jointly regulate the expression of target genes and compensate for each other. KDM1A, KDM3B, KDM6B, and KAT2B jointly participate in p21 transcriptional activation to promote gene expression. Because KAT2B coordinates with different epigenetic regulators, KAT2B can switch its role between transcriptional activation and repression by coordinating with different histone modification complexes.

[0077] In a second aspect, the present invention also provides the use of the above-mentioned KAT2B-binding histone demethylase complex in the preparation of an agent for inhibiting the proliferation of cholangiocarcinoma.

[0078] Specifically, KAT2B specifically binds to KDM1A, KDM3B, and KDM6B to regulate the expression of the downstream gene p21.

[0079] Exemplarily, the expression of the tumor suppressor gene p21 is promoted by the KAT2B binding to the histone demethylase complex.

[0080] Specifically, the KAT2B binds to the histone demethylase complex and promotes the overexpression of the gene p21 by participating in the transcriptional activation of the tumor suppressor gene p21.

[0081] Exemplarily, KAT2B increases the sensitivity of cholangiocarcinoma cells to HDAC inhibitors, thereby inhibiting the growth of cholangiocarcinoma cells.

[0082] In a third aspect, the present invention further provides a drug for inhibiting the proliferation of bile duct cancer, wherein the drug is a liposome nanoparticle, and the drug comprises a KAT2B overexpression plasmid and an HDAC inhibitor.

[0083] Exemplarily, the mass ratio of the KAT2B overexpression plasmid to the HDAC inhibitor is 18-25:1.

[0084] Exemplarily, the HDAC inhibitor is Vorinostat.

[0085] In a fourth aspect, the present invention also provides a method for preparing the above-mentioned medicament, the preparation method comprising:

[0086] Step (1): dissolving egg yolk phosphatidylcholine E80, cholesterol Chol, KAT2B overexpression plasmid and HDAC inhibitor in a solvent to obtain a drug solution;

[0087] Step (2): removing the solvent by rotary evaporation to obtain a lipid film;

[0088] Step (3): hydrating the lipid film to form a liposome solution;

[0089] Step (4): Ultrasonicate the liposome solution to obtain a uniform liposome drug-loaded solution.

[0090] Illustratively, in step (1), the solvent is a mixture of chloroform and methanol.

[0091] Exemplarily, the volume ratio of chloroform to methanol is 3-4:1.

[0092] Illustratively, in the drug solution of step (1), the concentration of egg yolk phosphatidylcholine E80 is 1-2 mg / mL, the concentration of cholesterol Chol is 0.3-0.5 mg / mL, the concentration of KAT2B overexpression plasmid is 21-33 μg / mL, and the concentration of HDAC inhibitor is 1.2-1.3 μg / mL.

[0093] Exemplarily, step (2) includes: placing the drug solution in an eggplant-shaped bottle, and then rotary evaporating it in a water bath at 45 degrees Celsius for 45 minutes to remove the organic solvent and obtain a lipid film.

[0094] Exemplarily, step (3) includes: using PBS (phosphate buffered saline) at room temperature to fully hydrate the lipid film to form a liposome solution;

[0095] Exemplarily, step (4) includes: transferring the liposome solution into a vial and placing it in a beaker containing ice cubes, and performing ultrasonic treatment using a cell disruptor ultrasonic probe with a power of 400 W (working for 2 seconds, resting for 3 seconds, and a total of 8 minutes) to form a uniform liposome drug-loaded solution.

[0096] Example 1

[0097] This example is used to illustrate that KAT2B binds to histone demethylase to regulate downstream target genes.

[0098] 1. Identification and verification of KAT2B interacting proteins

[0099] Identification: First, construct HUCCT1 cells that stably express FLAG-tagged KAT2B or empty vector, then prepare cell extracts and affinity purify with anti-FLAG affinity gel. Separate using SDS-PAGE gel and perform silver staining (results as shown in Figure 6 ). The immunoprecipitated proteins in the specific bands were gel extracted with the carrier, digested with trypsin, and detected by liquid chromatography-mass spectrometry. Because KAT2B plays an important role in transcriptional regulation, we selected proteins involved in gene expression regulation from more than 700 KAT2B interacting proteins. It is worth noting that the analysis found that many epigenetic regulatory proteins belong to the KDM family. KDM consists of two evolutionarily conserved families, one is the lysine-specific demethylase (LSD) in the KDM1 subfamily, and the other is the histone demethylase (JMJs, JHDMs or JMJDs) containing the Jumonji C (JmjC) domain. The interacting proteins we found include these two families. This epigenetic mark has a broad and dynamic regulatory effect on histone modification and chromatin remodeling. Therefore, KAT2B acts together or cross-acts with KDM1A, KDM3B and KDM6B on the same target gene site, thereby regulating the transcription of downstream genes.

[0100] Verification: Total proteins from HUCCT1 and RBE cells were extracted and immunoprecipitated using antibodies that detect endogenous proteins. IP was performed with anti-KAT2B antibodies, followed by IB with anti-HAT1, KDM1A, KDM3B, and KDM6B antibodies. The results showed that these proteins interacted with KAT2B in HUCCT1 and RBE cells (results shown in Figure 7). Since KAT2B, also known as PCAF (human p300 / CBP-associated factor), contains a histone acetyltransferase (HAT) domain, HAT1 can also be used as a positive control for this IP experiment. Then, in turn, IP with antibodies against HAT1, KDM1A, KDM3B, and KDM6B and IB with antibodies against KAT2B also supported that KAT2B can effectively co-immunoprecipitate with these components (results are shown in Figure 8 ). In addition, immunofluorescence colocalization was used to detect whether KAT2B colocalized with the above-mentioned histone demethylases in cells. The same HUCCT1 cell line was incubated with anti-KAT2B, KDM1A, KDM3B and KDM6B antibodies, and then incubated with two different color fluorescent dyes and DAPI in sequence. The experimental results showed that KAT2B colocalized with KDM1A, KDM3B and KDM6B and existed in the cell nucleus (the results are shown in Figure 2). Fig. 9 ).

[0101] The above results confirm that KAT2B can interact with histone demethylases DM1A, KDM3B and KDM6B in vivo.

[0102] 2. Transcriptome analysis of KAT2B

[0103] Since KAT2B interacts with histone demethylases DM1A, KDM3B, and KDM6B, and all of them are closely related to gene transcriptional regulation, in order to further study and explore the role of KAT2B in transcriptional regulation of cholangiocarcinoma, high-throughput RNA deep sequencing (RNA-seq) was performed on KAT2B knockdown HUCCT1 cells and control cells (the results are shown in Fig.10 ), RNA-seq analysis showed that 515 genes changed in expression when KAT2B was lost. Gene set enrichment analysis (GSEAs) showed (e.g. Fig.11 ), in the case of KAT2B knockdown, genes were enriched in epithelial-mesenchymal transition, G2 / M checkpoint, E2F, UV-induced DNA damage and repair, MITOTIC_SPINDLE, and Hedgehog signaling pathways. To identify the functional processes associated with the target genes regulated by KAT2B, KEGG pathway enrichment analysis was performed and these genes were classified into various cell signaling pathways, including Rap1 signaling pathway, PI3K / AKT signaling pathway, thyroid hormone synthesis, focal adhesion, small cell lung cancer, and JAK / STAT signaling pathway, all of which are related to cell growth, migration, and invasion ( Fig.12The top categories in the biological process (BP) analysis were extracellular matrix assembly, angiogenesis, positive regulation of active oxidative metabolic processes, signal transduction, cell-cell adhesion, positive regulation of smooth muscle cell migration, and cellular response to cAMP, indicating that KAT2B is involved in cell metabolism regulation and proliferation ( Fig.13 ). Molecular function (MF) analysis identified many major roles, including protein binding, calcium ion binding, cholesterol binding, transcription factor activity, and oxidoreductase activity, suggesting that KAT2B is involved in epigenetic regulation, such as DNA / RNA or histone modification and chromatin remodeling ( Fig.14 In addition, cell component (CC) analysis showed that KAT2B was associated with axons, endoplasmic reticulum lumen, protein extracellular matrix, endoplasmic reticulum membrane, growth cones, focal adhesions, Golgi apparatus, membrane rafts and cell junctions, indicating that KAT2B is involved in protein synthesis ( Fig.15 ).

[0104] 3. Transcriptional regulation of target genes by KAT2B, KDM1A, KDM3B and KDM6B

[0105] To validate the RNA-seq analysis results, we selected nine representative genes and verified their expression in HUCCT1 and RBE cells using quantitative real-time PCR (qPCR). Fig.16a and Fig.16b As shown in Figure 2, qPCR results showed that compared with the control siRNA, when KAT2B, KDM1A, KDM3B and KDM6B were knocked down, the mRNA levels of CDKN1A, CDKN2B, CDKN1C, PTPN12, CYB5R2 and LIMA1 decreased to varying degrees; while after knocking out KAT2B, KDM1A, KDM3B and KDM6B, the mRNA levels of CDK6, CDK14 and TPM4 increased. Since TPM4 is involved in tumor invasion and migration, KAT2B can inhibit the invasion and migration of cholangiocarcinoma cells, and one of the reasons is that KAT2B regulates the transcriptional expression of TPM4. Fig.17a and Fig.17b KAT2B, KDM1A, KDM3B and KDM6B were knocked down in HUCCT1 and RBE cells. Among the target genes found, there are multiple members of the cell cycle-dependent kinase (CDKs) family. Therefore, KAT2B inhibits the proliferation of cholangiocarcinoma cells by affecting the transcription of genes related to the cell cycle pathway.

[0106] 4. Molecular mechanism of KAT2B binding to histone demethylase complex to regulate gene transcription

[0107] KAT2B can acetylate histones at the H3K14 and H4K8 sites on gene promoters, when the chromosomes are in an open state, thereby activating the expression of downstream genes; while KDM1A, KDM3B and KDM6B are all histone demethylases, but demethylation at different sites will lead to gene expression or inhibition. Histone demethylases are roughly divided into two families: LSD and JMJD. LSD1 can specifically remove single and double methylation modifications of histone H3K4 and H3K9, while the JMJD family can remove lysine trimethylation modifications. Therefore, we detected whether KAT2B regulates the expression of target genes by binding to their promoters with KDM1A, KDM3B and KDM6B. In order to verify the results of RNA-seq analysis, we selected 6 representative target genes that are positively regulated by KAT2B. ChIP experiments were performed in HUCCT1 cells using anti-KAT2B, KDM1A, KDM3B and KDM6B or control IgG antibodies. ChIP results were quantitatively analyzed by qPCR, and it was found that KAT2B, KDM1A, KDM3B and KDM6B jointly occupied the promoter of CDKN1A ( Fig.18 ). This result supports the conclusion that KAT2B, KDM1A, KDM3B and KDM6B occupy the promoter of common target genes as a functional cooperative protein complex. And we found that six other target genes are specifically regulated by different KAT2B complexes. For example, KAT2B and KDM6B specifically co-occupy the promoters of CDKN2B, CYB5R2, and PTPN12. KAT2B, KDM1A and KDM6B specifically co-occupy the promoter of OSGIN1, but not the promoter of CDKN1C. Next, we performed ChIP experiments on tumor cells with knockdown of KAT2B, KDM1A, KDM3B and KDM6B, respectively. ChIP qPCR results analysis showed that the knockdown of KAT2B, KDM1A, KDM3B and KDM6B resulted in a significant reduction in the binding of the remaining three proteins to the promoter of CDKN1A, indicating that KAT2B can specifically affect the binding of KDM1A, KDM3B and KDM6B to the promoters of target genes. Notably, knockdown of KAT2B, KDM1A, KDM3B, and KDM6B resulted in a significant decrease in H3K14ac and H4K8ac at the CDKN1A promoter ( Fig.19 ). To further examine whether KAT2B affects the binding of KDM1A, KDM3B and KDM6B to chromatin, we knocked down KAT2B, KDM1A, KDM3B and KDM6B in HUCCT1 and RBE cells, respectively, and extracted chromatin-bound proteins from them. Fig. 20As shown in the figure, compared with the control group, after knocking down KAT2B, the amount of chromatin-bound KDM3B and KDM6B was slightly reduced, but LSD1 was slightly increased. Similarly, after knocking down KDM1A, KDM3B and KDM6B, the amount of chromatin-bound another three proteins was reduced.

[0108] In summary, KAT2B specifically binds to KDM1A, KDM3B, and KDM6B, and promotes the acetylation of H3K14 and H4K8 on the p21 promoter through epigenetics. KAT2B is associated with KDM1A, KDM3B, and KDM6B, promoting the expression of the tumor suppressor gene p21. Moreover, knockdown of KDM1A, KDM3B, and KDM6B simultaneously reduced the expression of p21, indicating that KAT2B binds to KDM1A, KDM3B, and KDM6B to co-regulate the expression of target genes and compensate for each other. KDM1A, KDM3B, KDM6B, and KAT2B jointly participate in p21 transcriptional activation to promote gene expression. Because KAT2B coordinates with different epigenetic regulators, KAT2B can switch its role between transcriptional activation and repression by coordinating with different histone modification complexes.

[0109] Example 2

[0110] This example is used to illustrate that KAT2B inhibits the proliferation of cholangiocarcinoma cells by regulating p21.

[0111] 1. Knockout of KAT2B leads to increased proliferation of cholangiocarcinoma cells, which can be rescued by overexpression of p21

[0112] First, EdU assay was performed and it was found that KAT2B knockdown resulted in an increase in cell proliferation rate compared with the control group, while cells overexpressing p21 while knocking out KAT2B showed a proliferation rate similar to that of the control group, indicating that KAT2B affects the proliferation of cholangiocarcinoma cells depending on the expression of p21 ( Fig.21 ). Fig. 22 The quantitative statistical results of the EdU experiment are shown. In addition, HUCCT1 and RBE cells were transfected with the specified specific shRNA and then overexpressed with p21, and the trans-well invasion assay was performed on them. The infiltrated cells were stained and counted, and the results are shown in Fig.23 As shown, the images represent a perspective under each microscope. Through Trans-well invasion experiments, it was found that knockdown of KAT2B led to a significant increase in the invasive ability of HUCCT1 and RBE cells, and on this basis, overexpression of p21 could reverse this promotion phenomenon. p21 can rescue the excessive invasive ability of cancer cells with KAT2B knockout ( Fig.23 ). Fig.24The quantitative statistical results of the invasion experiment indicate that the putative tumor suppressor function of KAT2B is related to p21. The knockout and overexpression lentivirus transfection quality check of the cells was verified by Western Blots. Western Blots verified the effectiveness of the knockout and overexpression lentivirus used in these experiments. We also observed that with the knockout of KAT2B, the expression of the corresponding downstream targets CDKN1A and CDKN2B also showed the same decreasing trend, which further illustrates that KAT2B acts on p21 to play a role in inhibiting cholangiocarcinoma ( Fig.25 ).

[0113] 2. In vivo experiments demonstrate that KAT2B inhibits the proliferation and metastasis of cholangiocarcinoma cells

[0114] HUCCT1 cells stably expressing shKAT2B or overexpressing KAT2B were injected subcutaneously into BALB / c nude mice, and tumor size was measured every 3 days for four weeks to monitor tumor growth. The results showed that KAT2B knockdown significantly increased tumor growth rate, while KAT2B expression effectively inhibited tumor growth ( Fig.26 ). Fig. 27 The tumor weight / volume of mice in the KAT2B interference or KAT2B overexpression groups were compared with those in the control group. To evaluate the function of KAT2B in tumor metastasis, HUCCT1 cells stably expressing firefly luciferase were infected with lentivirus carrying shKAT2B, shSCR, Vector or overexpressing KAT2B. These cells were then injected into immunocompromised severe combined immunodeficient (NOD-SCID) male mice (n=5) through the tail vein; after 4 weeks, bioluminescence imaging of metastases was quantified using the IVIS imaging system. It was found that KAT2B knockdown significantly increased the number of tumor nodules in vivo and lung metastasis of cholangiocarcinoma cells ( Figure 28-30 ). These results suggest that KAT2B can play an important role in tumor proliferation and metastasis.

[0115] Example 3

[0116] This example uses KAT2B to increase the sensitivity of cholangiocarcinoma cells to the histone deacetylase (HDAC) inhibitor Vorinostat.

[0117] KAT2B can inhibit the proliferation of cholangiocarcinoma cells through acetylation activity. We further considered whether the degree of inhibition of deacetylase would enhance this effect. Vorinostat is often used in the treatment of tumors as a histone deacetylase inhibitor. When deacetylase inhibitors are used, the function of acetylase will not be eliminated, thereby increasing acetylation. Therefore, a CCK8 experiment was conducted, and it was found that the cell viability of cholangiocarcinoma cells overexpressing KAT2B was significantly reduced after treatment with Vorinostat compared with the control group; in addition, cell viability is concentration-dependent, and the higher the concentration, the stronger its sensitization effect ( Fig.31 ). The same results were found through clone formation experiments. KAT2B can effectively increase the sensitivity of cells to Vorinostat, and the number of colony formation is significantly reduced ( Fig.32 ). These findings confirm that KAT2B can enhance the inhibitory effect of Vorinostat on cholangiocarcinoma cells.

[0118] Example 4

[0119] This embodiment provides a drug for inhibiting the proliferation of cholangiocarcinoma, the drug comprising a KAT2B overexpression plasmid and an HDAC inhibitor, the mass ratio of the KAT2B overexpression plasmid to the HDAC inhibitor is 20:1, and the HDAC inhibitor is Vorinostat.

[0120] Example 5

[0121] This embodiment provides a method for preparing a medicament for inhibiting the proliferation of bile duct cancer, comprising:

[0122] (1) Take 4.92 mg of E80, 1.25 mg of Chol, 0.1 mg of KAT2B overexpression plasmid and 5 ug of HDAC inhibitor (Vorinostat) and dissolve them in 4 mL of a mixture of chloroform and methanol. The molar ratio of chloroform to methanol is 3:1.

[0123] (2) The mixed solution was placed in a 50 mL eggplant-shaped bottle, mixed evenly, and then subjected to rotary evaporation in a water bath at 45°C for 45 min to remove the organic reagent to obtain a lipid film.

[0124] (3) The lipid film was fully hydrated with PBS at room temperature.

[0125] (4) The above fully hydrated solution was placed in a 10 ml vial, and the vial was placed in a 50 ml beaker with ice, and then ultrasonicated using a cell disruptor ultrasonic probe (power 400 W, working time 2 s, rest 3 s, ultrasonication 8 minutes) to obtain a liposome drug-loaded solution, i.e., liposome nanoparticles, recorded as KV nanoparticles.

[0126] Fig.33This is the particle size distribution diagram of the KV nanoparticles obtained in this example; the average particle size of the KAT2B-Vorinostat liposome nanoparticles is 197.9 nm.

[0127] Fig.34 The surface potential detection results of the KV nanoparticles and the control nanoparticles (without Vorinostat and KAT2B overexpression plasmid) obtained in this example, the average surface potential of the control nanoparticles is -47.24 (mV), and the average surface potential of the KAT2B-Vorinostat liposome nanoparticles is -52.33 (mV).

[0128] Fig.35 This is an electron microscopic image of the KV nanoparticles obtained in this example. It can be seen from the image that the liposome nanoparticles are spherical.

[0129] Fig.36 This is a statistical diagram of the encapsulation efficiency of the KAT2B overexpression plasmid and Vorinostat in the KV nanoparticles obtained in this example. The encapsulation efficiency of the KAT2B overexpression plasmid is 75.0%±3.0%, and the encapsulation efficiency of Vorinostat is 83.3%±1.5%.

[0130] Fig.37 This is a statistical diagram of the drug loading rates of the KAT2B overexpression plasmid and Vorinostat in the KV nanoparticles obtained in this example. The drug loading rate of the KAT2B overexpression plasmid is 5.86%±0.38%, and the drug loading rate of Vorinostat is 6.37%±1.4%.

[0131] Fig.38 and Fig.39 The effect of KV nanoparticles obtained in this example on the growth of cholangiocarcinoma cells is shown in Figure 2. Specifically, 800 HUCCT1 cells were plated in each well of a 6-well plate, and control nanoparticles (without Vorinostat and KAT2B overexpression plasmid), Vorinostat, and KV nanoparticles obtained in this example were added, and crystal violet was used to stain and photograph after 10 days (as shown in Figure 2). Fig.38 ), analyze the number of clones formed and perform statistics (such as Fig.39 ), the results showed that the number of clones formed in the Vorinostat group was about 50% of that in the control group, while the number of clones formed in the KV nanoparticle group was about 20% of that in the control group, indicating that KV nanoparticles have a better anti-cholangiocarcinoma cell growth effect than Vorinostat.

[0132] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily conceived by any technician familiar with the technical field within the technical scope disclosed by the present invention should be covered within the protection scope of the present invention.

Claims

1. A KAT2B-binding histone demethylase complex, characterized in that: The KAT2B-binding histone demethylase complex includes KAT2B, KDM1A, KDM3B and KDM6B.

2. Use of the KAT2B-binding histone demethylase complex according to claim 1 in the preparation of an agent for inhibiting the proliferation of cholangiocarcinoma.

3. The use according to claim 2, characterized in that: The KAT2B binds to the histone demethylase complex to promote the expression of the tumor suppressor gene p21.

4. The use according to claim 3, characterized in that: The KAT2B binds to the histone demethylase complex and promotes the expression of gene p21 by participating in the transcriptional activation of the tumor suppressor gene p21.

5. The use according to claim 2, characterized in that: KAT2B increases the sensitivity of cholangiocarcinoma cells to HDAC inhibitors.

6. A drug for inhibiting the proliferation of bile duct cancer, characterized in that: The medicament is a liposome nanoparticle, and the medicament comprises a KAT2B overexpression plasmid and an HDAC inhibitor.

7. The agent according to claim 6, characterized in that The mass ratio of the KAT2B overexpression plasmid to the HDAC inhibitor is 18-25:

1.

8. The medicament according to claim 6, characterized in that The HDAC inhibitor is Vorinostat.

9. The method for preparing the medicament according to any one of claims 6 to 8, characterized in that: The preparation method comprises: Step (1): dissolving egg yolk phosphatidylcholine E80, cholesterol Chol, KAT2B overexpression plasmid and HDAC inhibitor in a solvent to obtain a drug solution; Step (2): removing the solvent by rotary evaporation to obtain a lipid film; Step (3): hydrating the lipid film to form a liposome solution; Step (4): Ultrasonicate the liposome solution to obtain a uniform liposome drug-loaded solution.

10. The method according to claim 9, characterized in that In step (1), the solvent is a mixture of chloroform and methanol.